This study is NOT currently recruiting participants.
Number
001948-C
Sponsoring Institute
National Cancer Institute (NCI)
Recruitment Detail
Type: Recruitment has not started Gender: Male & Female Min Age: 18 Years Max Age: 120 Years
Referral Letter Required
No
Population Exclusion(s)
Non-English Speaking;Children;Fetuses;Pregnant Women;Neonates
Keywords
Questionnaire; Side Effects; Toxicity
Recruitment Keyword(s)
None
Condition(s)
Malignant Neoplasms; Carcinoma
Investigational Drug(s)
Investigational Device(s)
Intervention(s)
Other: Patient Reported Outcomes (PROs)
Supporting Site
National Cancer Institute
Many newer cancer treatments use immunotherapy. That is, agents are given to cause the immune system to fight cancer cells. But some people who have had these treatments get bad side effects. They may develop issues in the skin, liver, and other organs. Researchers want to learn more about how immunotherapies may affect people with cancer.
Objective:
To monitor side effects in people with cancer who are treated with immunotherapies.
Eligibility:
People aged 18 years and older with cancer. They must be either (1) starting immunotherapy; or (2) having immune-related side effects while receiving immunotherapy.
Design:
Participants medical records will be reviewed.
Participants will undergo their prescribed cancer treatments. They will be watched for side effects. They will have blood drawn just for research.
Participants will fill out questionnaires once a week for the first 9 weeks of their treatment. They will answer questions about their general health and how they are feeling. These questionnaires can be done on a website or on paper. Each takes about 15 minutes.
From week 9 to week 13, participants will fill out questionnaires only when their tumors are imaged.
Participants will have a follow-up visit 30 days after their treatment ends. They may continue having follow-up visits to watch for long-term effects of immunotherapy; these visits may be by a clinic visit or a phone call.
Sponsoring Institution: MD Anderson Cancer Center
--Back to Top--
INCLUSION CRITERIA: -Patients must be able to understand and be willing to sign a written informed consent document. -Patients must be under consideration or currently enrolled for any regimen that includes an immunotherapeutic agent (monotherapy or combination therapy).
-Patients must be able to understand and be willing to sign a written informed consent document.
-Patients must be under consideration or currently enrolled for any regimen that includes an immunotherapeutic agent (monotherapy or combination therapy).
Principal Investigator
Referral Contact
For more information: